Muhammad Ali Muslimani

Muhammad Ali Muslimani

Auto-generated profile, based on publicly available information

Muhammad Ali Muslimani

Department of Clinical, Surgical, Diagnostic and Pediatric Science, University of Pavia, Pavia, Italy, unipv.eu

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 June 2019 in Autoimmune Diseases
Verified
Journal Article
Open access
PDF file
JPJames C. Di Palma-Grisi
James C. Di Palma-Grisi
KVKesav Vijayagopal
Kesav Vijayagopal
MMMuhammad A. Muslimani
Muhammad A. Muslimani
Background. Monoclonal antibodies constitute a potent and broadly tolerable drug class, representing for some conditions the first newly approved treatment in years. As such, many are afforded “fast-track” or “breakthrough therapy” designations by the U.S. Food and Drug Administration, leading to provisional approval before Phase III clinical trials are reported. Although these drugs are usually safe, some patients experience life-threatening complications—myositis and encephalitis have led to permanent or temporary recalls. Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome is a hypersensitivity condition easily missed due to its long incubation period and nonspecific presentation. This minireview is primarily intended as an abbreviated guide for practitioners who may be using these powerful treatments. Methodology. We searched PubMed using a string of symptoms consistent with DRESS syndrome and monoclonal antibodies approved by the FDA since 2015. Then, we excluded studies reporting dermatological complications of reactivation of nonherpetic infection, immunodeficiency-related infection, or reactions to the injection site or infusion. We searched for and accessed prior reviews and background studies via PubMed, Mendeley, and Google Scholar. Results. Two cases of DRESS syndrome were identified in the literature, both the result of treatment with daclizumab. There was one additional case of encephalitis without cutaneous symptoms caused by daclizumab. Drug-induced hypersensitivity dermatitis was reported following treatment with nivolumab and two cases of combination treatment with ipilimumab and either nivolumab or durvalumab produced maculopapular rash and bullae in the first patient and lichenoid dermatitis and blisters in the second patient. Conclusions. Daclizumab was the only recently approved monoclonal antibody associated with DRESS syndrome as such. Limitations in the diagnostic reliability of DRESS syndrome as a clinical entity and the lack of negative clinical trial reporting suggest enhanced vigilance on the part of clinicians and regulators may be warranted.

15 August 2019 in BMJ Case Reports
Verified
Journal Article
Closed access
MMMuhammad A Muslimani
Muhammad A Muslimani
JPJames Di Palma-Grisi
James Di Palma-Grisi
A 26-year-old man undergoing therapy with 45 mg ustekinumab (Stelara) for chronic psoriasis vulgaris was referred by his general practitioner to an infectious diseases department for fatigue, fever, night sweating, generalised lymphadenomegaly and unexplained weight loss. Physical examination revealed bilateral occipital, cervical, axillary and inguinal lymphadenomegalies in addition to splenomegaly. Preliminary investigation revealed elevated Plasmodium lactate dehydrogenase and an inversion of the CD4/CD8 ratio. Whole-body spiral CT scanning with and without contrast showed splenomegaly and highlighted supradiaphragmatic and subdiaphragmatic lymphadenopathies. A complete Infectious Disease Test Panel revealed high levels of anti-Toxoplasma gondii antibodies. Immunoglobulin G avidity was negative. Peripheral blood lymphocyte phenotyping was performed to exclude underlying lymphatic neoplasia. The diagnosis of severe acute toxoplasmosis infection in the setting of immune response modifiers was made. Ustekinumab was suspended indefinitely and the patient underwent monthly serological tests to monitor the immune response until all symptoms resolved and the serological testing was negative for Toxoplasma.

1 January 2026 in Case Reports in Ophthalmological Medicine
Verified
Journal Article
Open access
MMMuhammad Ali Muslimani
Muhammad Ali Muslimani
AAAlberto Ardizzone
Alberto Ardizzone
SRSilvia Rossi
Silvia Rossi
FSFrancesco Siviero
Francesco Siviero
ALArmanda Leka
Armanda Leka
AMAngela Maria Di Matteo
Angela Maria Di Matteo
Background: Ocular tuberculosis (TB) is an uncommon yet potentially vision‐threatening manifestation of Mycobacterium tuberculosis , particularly difficult to diagnose in immunocompromised individuals. The increasing use of anti–tumor necrosis factor‐ α (anti–TNF‐ α ) agents has markedly heightened the risk of TB reactivation, often with disseminated or extrapulmonary involvement despite negative baseline screening. Case Presentation: We describe a 52‐year‐old woman with rheumatoid arthritis receiving long‐term adalimumab and methotrexate who developed disseminated TB with pulmonary, splenic, and ocular involvement after 12 years of anti–TNF‐ α therapy. Baseline screening had shown a negative tuberculin skin test and an indeterminate interferon‐ γ release assay. She presented with constitutional and respiratory symptoms, whereas chest computed tomography demonstrated diffuse micronodular infiltrates consistent with miliary TB. Microbiological confirmation was obtained via bronchoalveolar lavage. Ophthalmologic evaluation revealed bilateral choroidal granulomas with subretinal edema, leading to a diagnosis of ocular TB. Standard antitubercular therapy (ATT) was initiated but required modification due to drug‐induced liver injury. Adjunctive systemic corticosteroids were introduced after antimicrobial therapy and gradually tapered. The patient achieved progressive clinical, radiological, and ophthalmologic improvement, with gradual regression of choroidal lesions. Discussion: This case underscores the persistent long‐term risk of TB reactivation during prolonged anti–TNF‐ α therapy and highlights the limitations of current screening strategies in immunosuppressed patients. Ocular TB requires integration of systemic, clinical, and imaging findings; in this patient, microbiologically confirmed disseminated TB together with characteristic bilateral choroidal granulomas supported a definitive diagnosis. Management relies on prompt ATT, discontinuation of immunosuppression, and judicious use of adjunctive corticosteroids. Long‐term follow‐up is essential given the risk of persistent lesions and late recurrence. Reintroduction of biologic therapy may be feasible in selected cases but requires careful risk stratification. Conclusion: TB should remain a diagnostic consideration in patients receiving biologic therapy who develop compatible systemic or ocular manifestations, even after long‐term treatment and negative baseline screening. Close multidisciplinary collaboration is essential for the diagnosis and management of ocular TB in this population.

1 January 2026 in Case Reports in Infectious Diseases
Verified
Journal Article
Open access
FSFrancesco Siviero
Francesco Siviero
MMMuhammad A. Muslimani
Muhammad A. Muslimani
ALArmanda Leka
Armanda Leka
VAVittorio Arici
Vittorio Arici
ABAntonio Bozzani
Antonio Bozzani
ESElena Seminari
Elena Seminari
Background: Ventricular assist devices (VADs) are increasingly used as a bridge to transplantation or as destination therapy in heart failure patients. Fungal bloodstream infections, though less common than bacterial infections in VAD recipients, carry the highest mortality. Arterial involvement, including mycotic thrombus formation, is exceptionally rare and poses diagnostic and therapeutic challenges. We report the first documented case of candidemia complicated by femoral arterial mycotic thrombus in an LVAD recipient. Case Presentation: A 50‐year‐old man developed Candida albicans fungemia four months after undergoing LVAD implantation for severe dilated cardiomyopathy. Intravenous caspofungin was initiated due to potential azole–warfarin interactions. Blood cultures rapidly became negative, and multimodal imaging revealed no LVAD or endovascular involvement. On day 37 of ongoing antifungal therapy, ultrasound identified a subocclusive femoral artery thrombus at a prior cannulation site. Surgical thrombectomy confirmed C. albicans within the clot. Antifungal therapy continued, and the patient underwent successful emergency heart transplantation 15 days later. Discussion: Invasive fungal vascular infections may occur despite negative blood cultures and absence of detectable device involvement. Prior arterial trauma likely predisposed to localized fungal colonization. Management required careful risk assessment, prompt surgical intervention, and individualized antifungal therapy. Multidisciplinary collaboration among infectious disease specialists, radiologists, cardiologists, and cardiac surgeons was critical. Definitive source control through device explantation and transplantation was essential for curative intent. Device removal should be considered on a case‐by‐case basis, even when imaging shows no infectious foci, as prognosis without it may be poor. Fungal infection does not necessarily contraindicate transplantation, and early recognition combined with tailored therapy can optimize outcomes. Conclusions: Arterial Candida thrombus in LVAD recipients is rare but life‐threatening. High clinical suspicion, multimodal diagnostics, prompt surgical management, and individualized antifungal therapy are essential. Further studies are needed to define optimal antifungal strategies, surveillance, and transplant considerations for these high‐risk infections.

1 January 2026 in Case Reports in Hepatology
Verified
Journal Article
Open access
FSFrancesco Siviero
Francesco Siviero
MMMuhammad Ali Muslimani
Muhammad Ali Muslimani
SLSonia Lerta
Sonia Lerta
SFSofia Frattola
Sofia Frattola
PVPietro Valsecchi
Pietro Valsecchi
EBEnrico Brunetti
Enrico Brunetti
Background: Malignant and benign hepatic diseases may both present with systemic symptoms and necrotic liver cavities. Although rare and reported predominantly in East Asia, pyogenic liver abscess (PLA) can represent the initial manifestation of hepatocellular carcinoma (HCC), as necrotic tumors may mimic infectious abscesses. Case Presentation: A 63‐year‐old Italian man presented with a 2‐week history of fever and right upper quadrant pain. Computed tomography revealed a multiloculated lesion with irregular margins and a solid component in the right hepatic lobe, suggestive of a liver abscess, and empirical tigecycline therapy was initiated. Low‐titer Entamoeba spp. IgG antibodies were detected, and percutaneous aspiration yielded material initially mischaracterized as “anchovy paste,” raising suspicion for amoebic liver abscess. However, the patient failed to improve despite appropriate antiprotozoal therapy. Subsequent percutaneous drainage led to cavity resolution and symptom relief; all microbiological and parasitological tests were negative, and repeat Entamoeba serology became negative. Concurrent biopsy of the solid component revealed well‐differentiated pseudoglandular HCC. Magnetic resonance imaging demonstrated a biliary fistula associated with the neoplastic lesion, supporting a diagnosis of PLA secondary to HCC. The patient underwent right hepatectomy, complicated by intraoperative abscess rupture and postoperative intra‐abdominal abscesses caused by vancomycin‐resistant Enterococcus faecium . Discussion: PLA presenting as the initial manifestation of HCC is associated with poor prognosis, largely due to diagnostic delays. Limited clinical experience outside high‐prevalence regions and nonspecific clinical, laboratory, and imaging findings contribute to underrecognition of malignancy. Positive microbiological or serological results and transient clinical improvement during antimicrobial therapy do not exclude an underlying neoplasm. Liver biopsy and close radiologic follow‐up are essential in atypical or treatment‐refractory cases. Conclusion: PLA as a presenting feature of HCC is unusual, especially in Europe, yet poses substantial diagnostic and therapeutic challenges. Increased clinical awareness and early histopathological evaluation are crucial to avoid delayed oncologic diagnosis.

1 January 2025 in Case Reports in Infectious Diseases
Verified
Journal Article
Open access
MMMuhammad Ali Muslimani
Muhammad Ali Muslimani
VBValeria Brazzelli
Valeria Brazzelli
MLMarco Lucioni
Marco Lucioni
AMAngela Maria Di Matteo
Angela Maria Di Matteo
Raffaele BrunoRaffaele Bruno
Raffaele Bruno
EBEnrico Brunetti
Enrico Brunetti
Background: Q fever is a globally distributed zoonotic infection caused by Coxiella burnetii , exhibiting a broad clinical spectrum in both acute and chronic forms. While pneumonia, hepatitis, and endocarditis are well‐recognized manifestations, cutaneous involvement remains poorly characterized and likely underreported. Case Presentation: A 63‐year‐old male metalworker was admitted with a 2‐week history of high‐grade fever, dyspnea, anorexia, intractable hiccups, and profound asthenia. Physical examination revealed a diffuse, nonpruritic, blanchable macular rash on the back and sacral region. Extensive microbiological and autoimmune investigations were negative. Chest imaging demonstrated bilateral pneumonia, mediastinal lymphadenopathy, and a small pericardial effusion. Skin biopsy showed mild acanthosis, dermal capillary congestion, and superficial lymphohistiocytic infiltrates. Serological testing confirmed acute Q fever, with elevated Phase II C. burnetii antibody titers. Oral doxycycline led to complete resolution of fever and rash. Serial serology demonstrated a progressive decline in antibody titers, and the patient remained symptom‐free after 6 months. Discussion: This case highlights a rare parainfectious macular rash associated with acute Q fever—apparently the first reported in Italy. Cutaneous involvement in Q fever may represent a parainfectious immune‐mediated reaction. Its nonspecific appearance and lack of a characteristic distribution pattern often delay diagnosis. Conclusion: Clinicians should maintain a high index of suspicion for C. burnetii infection in patients with unexplained fever, pneumonia, and rash, even in the absence of direct animal exposure. Multidisciplinary evaluation and serial serology are pivotal for timely diagnosis, effective management, and monitoring of disease resolution.